Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | DHCR24 | Q15392 | 10/20 | 0.77 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.51 |
| ▸ | RORC | P51449 | 2/20 | 0.50 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.50 |
| ▸ | OSBP | P22059 | 1/20 | 0.50 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.50 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | CYP8B1 | Q9UNU6 | 1/20 | 0.48 |
| ▸ | GPR183 | P32249 | 1/20 | 0.46 |
| ▸ | RORA | P35398 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22099724 | 1.00 | USP2 (1.00) | USP2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL14360754 | 1.00 | USP2 (1.00) | USP2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL28606202 | 1.00 | USP2 (1.00) | USP2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL1957035 | 1.00 | USP2 (1.00) | USP2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL15529878 | 1.00 | USP2 (1.00) | USP2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL25035233 | 1.00 | USP2 (1.00) | USP2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL5571689 | 1.00 | USP2 (1.00) | USP2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL28186368 | 0.92 | MEN1 (0.85) | USP2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL2396787 | 0.91 | MEN1 (0.83) | USP2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL12869831 | 0.91 | MEN1 (0.83) | USP2MEN1KMT2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1477 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090590-A1 | NANOPARTICLE FORMULATIONS FOR THE DELIVERY OF DNA TO ADIPOSE TISSUE | Remedium Bio, Inc. (US) | 2026-04-30 | — | — | WO | claimed |
| US-12570991-B2 | Recombinant yeast strain having sterol productivity, preparation method therefor and use thereof | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2026-03-10 | — | — | US | claimed |
| US-20250114305-A1 | LIPIDIC COMPOUNDS, AND USES THEREOF | SANOFI (FR) | 2025-04-10 | — | — | US | claimed |
| US-20240408019-A1 | METHODS FOR FREEZING AND FREEZE-DRYING LIPID NANOPARTICLES (LNPs) AND LNPs OBTAINED WITH THE SAME | SANOFI PASTEUR INC. | 2024-12-12 | — | — | US | claimed |
| EP-4466248-A1 | LIPIDIC COMPOUNDS, AND USES THEREOF | Sanofi (FR) | 2024-11-27 | — | — | EP | claimed |
| EP-4441203-A1 | METHODS AND COMPOSITIONS RELATED TO ENGINEERED CANNABINOID RECEPTORS | Board of Regents, The University of Texas System (US) | 2024-10-09 | — | — | EP | claimed |
| US-20240309291-A1 | IONIZABLE CATIONIC LIPIDS | AKAGERA MEDICINES, INC. (US) | 2024-09-19 | — | — | US | claimed |
| EP-4412590-A1 | METHODS FOR FREEZING AND FREEZE-DRYING LIPID NANOPARTICLES (LNPS) AND LNPS OBTAINED WITH THE SAME | Sanofi (FR) | 2024-08-14 | — | — | EP | claimed |
| US-12018309-B2 | Optimization of C-5 sterol desaturation | DSM IP ASSETS B.V. (NL) | 2024-06-25 | — | — | US | claimed |
| US-20230398211-A1 | Liposomes Containing TLR4 Agonist, Preparation and Uses Thereof | SANOFI PASTEUR (FR) | 2023-12-14 | — | — | US | claimed |
| WO-2003026672-A1 | A METHOD OF REDUCING THE IN VIVO CHOLESTEROL ESTER TRANSFER PROTEIN MEDIATED TRANSFER OF CHOLESTERYL ESTERS BETWEEN HIGH DENSITY LIPOPROTEINS (HDL) AND LOW DENSITY LIPOPROTEINS (LDL) | FORBES MEDI-TECH INC. (CA) | 2003-04-03 | — | — | WO | claimed |
| WO-2002034241-A2 | COMPOUNDS COMPRISING A PHYTOSTEROL AND/OR PHYTOSTANOL MOIETY AND ASCORBIS ACID AND USE THEREOF AS WEIGHT REGULATING AGENTS | FORBES MEDI-TECH INC. (CA) | 2002-05-02 | — | — | WO | claimed |
| WO-2001077366-A1 | POSITIVE SELECTION METHOD, COMPOUNDS, HOST CELLS AND USES THEREOF | CUBIST PHARMACEUTICALS, INC. (US) | 2001-10-18 | — | — | WO | claimed |
| US-5955584-A | NON-PROTEIN ANTIGEN COMPOSED OF STEROID COMPONENT WITH 3 BETA HYDROXY OR 3 KETO GROUP AND QUATERNARY AMMONIUM SALT; FOR THERAPY AND IMMUNOASSAY DIAGNOSIS | CHARTER VENTURES (US) | 1999-09-21 | — | — | US | claimed |
| EP-0707489-A4 | ATHEROSCLEROTIC PLAQUE SPECIFIC ANTIGENS, ANTIBODIES THERETO, AND USES THEREOF | SCOTGEN BIOPHARMACEUTICALS INC (US) | 1998-07-29 | — | — | EP | claimed |
| EP-0707489-A1 | ATHEROSCLEROTIC PLAQUE SPECIFIC ANTIGENS, ANTIBODIES THERETO, AND USES THEREOF | Scotgen Biopharmaceuticals, Inc. (US) | 1996-04-24 | — | — | EP | claimed |
| EP-0405988-B1 | Use of superoxide dismutase in assays involving an oxidase | SANKYO CO (JP) | 1996-03-27 | — | — | EP | claimed |
| WO-1994025053-A1 | ATHEROSCLEROTIC PLAQUE SPECIFIC ANTIGENS, ANTIBODIES THERETO, AND USES THEREOF | SCOTGEN BIOPHARMACEUTICALS, INC. (US) | 1994-11-10 | — | — | WO | claimed |
| EP-0405988-A2 | Use of superoxide dismutase in assays involving an oxidase | Sankyo Company Limited (JP) | 1991-01-02 | — | — | EP | claimed |
| US-4224319-A | AMINO ACID, TRIGLYCERIDE, VITAMINS A AND E | MARCADET ERNEST | 1980-09-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230398211-A1 | Liposomes Containing TLR4 Agonist, Preparation and Uses Thereof | TLR4, TLR1, TLR7 | USP2 3893/4885MEN1 4220/4885KMT2A 3215/4885 |
| US-20250114305-A1 | LIPIDIC COMPOUNDS, AND USES THEREOF | NR1H2, NR1H3, LPAR3 | USP2 4227/4885MEN1 3319/4885KMT2A 3189/4885 |
| US-20240408019-A1 | METHODS FOR FREEZING AND FREEZE-DRYING LIPID NANOPARTICLES (LNPs) AND LNPs OBTAINED WITH THE SAME | CETP, LIPA, AUP1 | USP2 3827/4885MEN1 2725/4885KMT2A 4155/4885 |
| US-20240309291-A1 | IONIZABLE CATIONIC LIPIDS | PHOSPHO1, LIPA, ABHD16A | USP2 4644/4885MEN1 3359/4885KMT2A 2465/4885 |
| US-12570991-B2 | Recombinant yeast strain having sterol productivity, preparation method therefor and use thereof | ERG28, CYP46A1, CYP51A1 | USP2 2755/4885MEN1 1434/4885KMT2A 4082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.